LAMATTINA JOHN L
SEC CIK 1216074 · EDGAR
BoughtSold
Most active insiders at LGND, 12 months
| # | Insider | Title | Bought | Sold |
|---|---|---|---|---|
| 1 | Espinoza Octavio | CFO | — | $13.03M |
| 2 | Reardon Andrew | CLO, Sec | — | $8.77M |
| 3 | Haas Jason | Dir | — | $3.74M |
| 4 | LAMATTINA JOHN L | Dir | — | $2.44M |
| 5 | Gray Nancy Ryan | Dir | — | $1.35M |
| 6 | Aryeh Jason | Dir | — | $1.25M |
| 7 | KOZARICH JOHN W | Dir | — | $1.20M |
| 8 | Sabba Stephen L | Dir | — | $1.16M |
| 9 | Zimmermann Martine | Dir | — | $342.0K |
| 10 | Davis Todd C | CEO, Dir | — | — |
Transactions 15
| X | Filed | Traded | Ticker | Company | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| M | 2026-06-12 17:26 | 2026-06-10 | LGND | LIGAND PHARMACEUTICALS INC | LAMATTINA JOHN L | Dir | S - Sale | $250.88 | -4,591 | 27.0K | -15% | -$1.15M |
| D | 2026-06-09 19:41 | 2026-06-05 | LGND | LIGAND PHARMACEUTICALS INC | LAMATTINA JOHN L | Dir | A - Grant | $0.00 | +836 | 31.6K | +3% | $0 |
| D | 2026-03-31 | 2026-03-06 | LGND | LIGAND PHARMACEUTICALS INC | LAMATTINA JOHN L | Dir | M - OptEx | $114.15 | +2,161 | 32.9K | +7% | +$246.7K |
| D | 2026-03-31 | 2026-03-06 | LGND | LIGAND PHARMACEUTICALS INC | LAMATTINA JOHN L | Dir | S - Sale+OE | $200.76 | -2,161 | 30.7K | -7% | -$433.8K |
| DM | 2025-11-12 | 2025-11-07 | LGND | LIGAND PHARMACEUTICALS INC | LAMATTINA JOHN L | Dir | S - Sale+OE | $205.45 | -4,179 | 30.7K | -12% | -$858.6K |
| DM | 2025-11-12 | 2025-11-07 | LGND | LIGAND PHARMACEUTICALS INC | LAMATTINA JOHN L | Dir | M - OptEx | $67.78 | +4,179 | 32.8K | +15% | +$283.2K |
| D | 2025-06-10 | 2025-06-06 | LGND | LIGAND PHARMACEUTICALS INC | LAMATTINA JOHN L | Dir | A - Grant | $0.00 | +1,209 | 30.7K | +4% | $0 |
| D | 2024-12-02 | 2024-11-27 | LGND | LIGAND PHARMACEUTICALS INC | LAMATTINA JOHN L | Dir | S - Sale+OE | $123.65 | -2,406 | 29.5K | -8% | -$297.5K |
| D | 2024-12-02 | 2024-11-27 | LGND | LIGAND PHARMACEUTICALS INC | LAMATTINA JOHN L | Dir | M - OptEx | $52.30 | +2,406 | 31.9K | +8% | +$125.8K |
| D | 2024-06-18 | 2024-06-14 | LGND | LIGAND PHARMACEUTICALS INC | LAMATTINA JOHN L | Dir | A - Grant | $0.00 | +1,252 | 29.5K | +4% | $0 |
| D | 2023-06-13 | 2023-06-09 | LGND | LIGAND PHARMACEUTICALS INC | LAMATTINA JOHN L | Dir | A - Grant | $0.00 | +1,142 | 28.3K | +4% | $0 |
| 2023-01-17 | 2023-01-15 | IMNM | Immunome Inc. | LAMATTINA JOHN L | Dir | A - Grant | $4.00 | +15.1K | 67.0K | +29% | +$60.5K | |
| D | 2022-06-13 | 2022-06-10 | LGND | LIGAND PHARMACEUTICALS INC | LAMATTINA JOHN L | Dir | A - Grant | $0.00 | +1,004 | 26.4K | +4% | $0 |
| D | 2021-11-17 | 2021-11-16 | LGND | LIGAND PHARMACEUTICALS INC | LAMATTINA JOHN L | Dir | M - OptEx | $32.30 | +4,835 | 30.2K | +19% | +$156.2K |
| D | 2021-11-17 | 2021-11-16 | LGND | LIGAND PHARMACEUTICALS INC | LAMATTINA JOHN L | Dir | S - Sale+OE | $161.86 | -4,835 | 25.4K | -16% | -$782.6K |
Purchase Sale Sale after option exercise All abbreviations